Mustafa özgüroğlu
Istanbul Üniversitesi
H-index: 41
Asia-Turkey
Top articles of Mustafa özgüroğlu
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised … | The Lancet Oncology | Aristotelis Bamias Ian D Davis Matthew D Galsky José Á Arranz Eiji Kikuchi | 2024/1/1 |
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | JTO Clinical and Research Reports | Johan F Vansteenkiste Jarushka Naidoo Corinne Faivre-Finn Mustafa Özgüroğlu Augusto Villegas | 2024/3/1 |
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial | Annals of Oncology | AO Siefker-Radtke N Matsubara SH Park RA Huddart EF Burgess | 2024/1/1 |
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a … | Simon Chowdhury Anders Bjartell Neeraj Agarwal Byung H Chung Robert W Given | 2024/3/1 | |
Durvalumab±Tremelimumab+ Platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden | Clinical Cancer Research | Luis Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta | 2024/2/16 |
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. | Journal of Clinical Oncology | Joaquin Mateo Johann S de Bono Karim Fizazi Fred Saad Neal Shore | 2024/2/10 |
Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function | N Sengul I Gültürk M Yilmaz E Celik N Paksoy | 2024/4/1 | |
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary … | Journal of Thoracic Oncology | Martin Reck Fabrice Barlesi James Chih-Hsin Yang Virginie Westeel Enriqueta Felip | 2024/2/1 |
Seguridad y eficacia de nivolumab para el tratamiento de pacientes con carcinoma de células renales metastásico e insuficiencia renal | N Sengul I Gültürk M Yilmaz E Celik N Paksoy | 2024/3/8 | |
10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with … | Journal of Thoracic Oncology | S Kilickap M Özgüroğlu A Sezer M Gumus I Bondarenko | 2023/4/1 |
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8). | Mustafa Özgüroğlu Benjamin Philip Levy Hidehito Horinouchi Jinming Yu Ellie Grainger | 2023/6/1 | |
P2. 06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1≥ 50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 | Journal of Thoracic Oncology | M Gümüs S Kilickap A Sezer I Bondarenko M Özgüroğlu | 2023/11/1 |
OA01. 05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression+ Chemotherapy: EMPOWER-Lung 1 | Journal of Thoracic Oncology | MC Garassino S Kilickap M Özgüroğlu A Sezer M Gumus | 2023/3/1 |
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and … | Antoine Thiery-Vuillemin Fred Saad Andrew J Armstrong Mototsugu Oya Karina Vianna | 2023/6/1 | |
Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer | Lung Cancer | Gülin Alkan Şen Nihan Şentürk Öztaş Ezgi Değerli Günay Can Hande Turna | 2023/10/1 |
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium … | Clinical Genitourinary Cancer | Emre Yekedüz Serdar Karakaya İsmail Ertürk Deniz Tural Gökhan Uçar | 2023/2/1 |
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes … | Annals of Oncology | S Chowdhury A Bjartell N Agarwal BH Chung RW Given | 2023/5/1 |
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1 … | The Lancet Oncology | Mustafa Özgüroğlu Saadettin Kilickap Ahmet Sezer Mahmut Gümüş Igor Bondarenko | 2023/9/1 |
LBA2 First-line (1L) durvalumab (D)+ platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study | Immuno-Oncology and Technology | N Reinmuth M Özgüroğlu NB Leighl D Galetta I Hacibekiroglu | 2023/12/1 |
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized … | Journal for immunotherapy of cancer | Kohei Shitara Maria Di Bartolomeo Mario Mandala Min-Hee Ryu Christian Caglevic | 2023 |
Co-Authors
